Late Breaking Abstract submission opens on 1 September and the deadline is 15 September 2022 09:00 pm (21:00 hrs) Central European Time (CET) 

Definition 

• Late-breaking abstracts should highlight novel and practice changing studies. The late-breaking abstract deadline is not intended to be merely an extension of the general submission deadline. It will focus on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the conference.
• Examples of suitable late-breaking abstracts might include the results of a Phase II study showing anti-tumour activity in a novel context, an early clinical trial with novel proof-of-principle data, the demonstration of novel cancer biology with therapeutic implications; in each case the results should not have been fully available by the general abstract submission deadline.
• If the data and conclusions submitted in the abstract have been presented prior to the EORTC-NCI-AACR 2014 Symposium, the Scientific Committee reserves the right to deselect the abstract.  

Policy  

• Abstracts from translational, Phase I or Phase II for which preliminary data were not available at the time of the abstract submission deadline of 18 June, will be considered for presentation at the EORTC-NCI-AACR 2014 Symposium.
• Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. In this case, please ask for special consideration by email.
• Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.
• Late-breaking abstracts will be considered for oral presentation either in proffered papers sessions or in one of the Presidential sessions.  If a late-breaking abstract does not meet the criteria for oral presentation in one of these two sessions, the abstract will be rejected
• Late-breaking abstracts will undergo formal peer-review evaluation by the Scientific Committee. 

Submission

The first (presenting) author must: 

• Submit a late-breaking abstract by the submission deadline of 15 September 2022
• Complete the section on the reasons why this abstract should be considered as late-breaking (In order for the abstract to be considered late breaking, this section must be completed).
• Ensure that submission of the abstract follows the general abstract submission guidelines and regulations as specified in the Proffered Paper Guidelines.
• Ensure abstracts that include clinical trial data include the following information in the body of the abstract:
  • Trial abbreviation, Trial Registry Number or ID background, Objective, Design, Population studied (including sample size), Intervention, Outcome measure (s), analysis, Trial status, Trial sponsor(s)
• Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating “results to follow” or similar deferment will not be considered. 

Selection

• Abstracts will be judged solely on the data submitted.  The first (presenting) author will receive confirmation of acceptance or rejection before end September 2014 

EMBARGO POLICY FOR LATE BREAKING,  ORAL PRESENTATIONS AND ABSTRACTS SELECTED FOR MEDIA  

• Late-breaking abstracts submitted to the EORTC-NCI-AACR 2014 Symposium are considered to be embargoed until on the day of the presentation.
• Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been published or presented at the EORTC-NCI-AACR 2014 Symposium
• The first author and co-authors must not release the research/study to news media.
• If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online

Click here to submit your late breaking abstract